flow trial semaglutide all-cause mortality hazard ratio 🔴Cardiovascular outcomes with by severity of chronic kidney disease in type 2 diabetes: the trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants Frontiers | Effects of subcutaneous

Semaglutide works by activating GLP-1 receptors in your brain, which signals satiety and reduces appetitemeaning most patients naturally eat fewer calories without strict restriction

This supports more personalized supplementation conversations with your provider

Advertisement The reduced use of sick time translated to savings of up to 1.5 percent of a workers salary

If you have questions or would like to see whether physical therapy could support you during this phase, request an appointment at Bodyworks Physical Therapy

While recent case reports have suggested a possible link with GLP-1RA therapy and ION risk (particularly non-arteritic anterior ischaemic optic neuropathy), large-scale analyses examining formulation-specific risk have been lacking